MoneyWorks4Me

USFDA conducts inspection of Morepen Laboratories’ API manufacturing facility at Baddi

27 Mar 2023 Evaluate

The United States Food and Drug Administration (USFDA) has conducted an inspection of the API manufacturing facility, at Baddi, Himachal Pradesh, of Morepen Laboratories. The facility has been cleared by USFDA on March 24, 2023 without any adverse observation (NIL 483). 

Morepen Laboratories is engaged in the manufacturing and sale of APis/ Bulk Drugs, Home Diagnostics, Formulations and OTC products.

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..